Difference between revisions of "Team:ETH Zurich"

Line 75: Line 75:
 
#second {
 
#second {
 
     padding-top: 415px;
 
     padding-top: 415px;
 +
    text-align: right;
 
}
 
}
  
Line 130: Line 131:
 
<img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="CH" width="300px" align="left">
 
<img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="CH" width="300px" align="left">
 
</div>
 
</div>
−
<!--
+
 
 
CATE consists of the non-pathogenic bacterium  E. coli Nissle that has the intrinsic ability to home specifically in tumors. We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.
 
CATE consists of the non-pathogenic bacterium  E. coli Nissle that has the intrinsic ability to home specifically in tumors. We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.
  
 
Project description
 
Project description
  
−
-->
+
 
  
  

Revision as of 13:56, 7 October 2017



Cancer kills over 8 million people every year. That's the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.

Learn more
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors. We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites. Project description